20588 results
-
List item
Human medicine European public assessment report (EPAR): Evrysdi (updated)
Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021,
, Revision: 5, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Tezspire (updated)
tezepelumab, Asthma
Date of authorisation: 19/09/2022,
, Revision: 7, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Rybrevant (updated)
amivantamab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 09/12/2021,, 
, Revision: 3, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Alunbrig (updated)
brigatinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 22/11/2018,, Revision: 9, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Enhertu (updated)
trastuzumab deruxtecan, Breast Neoplasms
Date of authorisation: 18/01/2021,, , Revision: 12, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Vantobra (previously Tobramycin PARI) (updated)
Tobramycin, Respiratory Tract Infections; Cystic Fibrosis
Date of authorisation: 18/02/2019, Revision: 5, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): LysaKare (updated)
L-arginine hydrochloride, L-lysine hydrochloride, Radiation Injuries
Date of authorisation: 25/07/2019, Revision: 4, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Vyndaqel (updated)
tafamidis, Amyloidosis
Date of authorisation: 16/11/2011,, 
, 
, Revision: 27, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Opfolda (updated)
miglustat, Glycogen Storage Disease Type II
Date of authorisation: 26/06/2023, Revision: 1, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Scemblix (updated)
asciminib hydrochloride, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 25/08/2022,, , Revision: 3, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Levetiracetam Sun (updated)
levetiracetam, Epilepsy
Date of authorisation: 14/12/2011,
, Revision: 19, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Vaxneuvance (updated)
pneumococcal polysaccharide conjugate vaccine (adsorbed), Pneumococcal Infections
Date of authorisation: 13/12/2021,, Revision: 5, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Imjudo (updated)
Tremelimumab, Carcinoma, Hepatocellular
Date of authorisation: 20/02/2023,, Revision: 2, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Lutathera (updated)
lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017,, Revision: 10, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly) (updated)
tadalafil, Hypertension, Pulmonary
Date of authorisation: 01/10/2008, Revision: 17, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Procysbi (updated)
mercaptamine bitartrate, Cystinosis
Date of authorisation: 05/09/2013, Revision: 16, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Retsevmo (updated)
Selpercatinib, Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms
Date of authorisation: 11/02/2021,, , Revision: 8, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Prolia (updated)
denosumab, Bone Resorption; Osteoporosis, Postmenopausal
Date of authorisation: 26/05/2010, Revision: 27, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Fortacin (updated)
lidocaine, prilocaine, Sexual Dysfunction, Physiological
Date of authorisation: 15/11/2013, Revision: 12, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Vitrakvi (updated)
larotrectinib sulfate, Abdominal Neoplasms
Date of authorisation: 19/09/2019,, , Revision: 10, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Semglee (updated)
insulin glargine, Diabetes Mellitus
Date of authorisation: 23/03/2018,
, Revision: 9, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Tenkasi (previously Orbactiv) (updated)
oritavancin (diphosphate), Soft Tissue Infections; Skin Diseases, Bacterial
Date of authorisation: 19/03/2015, Revision: 14, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Tadalafil Lilly (updated)
tadalafil, Erectile Dysfunction
Date of authorisation: 22/03/2017, Revision: 6, Authorised, Last updated: 21/09/2023 -
List item
Human medicine European public assessment report (EPAR): Lynparza (updated)
Olaparib, Ovarian Neoplasms
Date of authorisation: 16/12/2014, Revision: 23, Authorised, Last updated: 21/09/2023 -
List item
Human medicine European public assessment report (EPAR): Fasenra (updated)
Benralizumab, Asthma
Date of authorisation: 08/01/2018, Revision: 12, Authorised, Last updated: 21/09/2023